ANNnewsCH banner
ANNnewsCH avatar
ANNnewsCH
@annnewsch
Subscribers5M
Views5.8B
Videos134K
ANNnewsCHPublished at May 23, 2026 at 03:15 PM0:39
【ニュース】世界初の食道がん治療薬を了承 「ウイルス」でがん細胞を破壊 #shorts thumbnail

【ニュース】世界初の食道がん治療薬を了承 「ウイルス」でがん細胞を破壊 #shorts

14 days agoActive window
shorts
Published time
May 23, 2026 at 03:15 PM
Duration
0:39
Video type
News & Politics
Channel region
Japan
Publish Timing Insight
Not enough timing data
This channel still lacks enough historical upload timing data. Let the channel accumulate more snapshots before evaluating the best timing.
Monetization Insight
No clear monetization tags yet
Focus on view growth, engagement quality, and topic competition to judge monetization potential.
Action Suggestion
Watch for sustained growth
The basic conditions are already in place. Keep watching 7-day views and revenue before deciding whether this topic should become a series.
Views
1.2K
Likes
14
Comments
1
Estimated Daily Revenue
-
Estimated Total Revenue
$0.03 - $0.11
RPM Range
$0.02 - $0.1
1D Views Gain
0
7D Views Gain
0
1D Likes Gain
0
7D Likes Gain
0
1D Comments Gain
0
7D Comments Gain
0
Velocity Score
0%
Topic Cluster
-
Video Description
食道のがん細胞をウイルスを使い破壊する治療薬について厚生労働省の部会が製造販売を了承しました。ウイルスを使った食道がんの治療薬は世界初だということです。  厚労省の専門部会が製造販売を了承したのはオンコリスバイオファーマの「テロメライシン」です。  食道がんの治療薬で、がん細胞でだけ増殖するように遺伝子組み換えをしたウイルスを患者の食道に投与し、がん細胞を破壊するということです。  臨床試験では36人の患者に放射線療法と併用して薬を投与した結果、18カ月後には半数にあたる18人のがんが消失しました。  ウイルスを使った食道がんの治療薬は世界初だということです。
Related Topics
Continue with closely related videos to judge topic depth and content format.
No topic keyword yet
Not enough related-topic video data yet.
Video FAQs

These FAQs clarify what this video page measures, why revenue is estimated, and how to use the page for content research.

What can you learn from this video analytics page?

This page shows views, likes, comments, RPM and revenue estimates, publish timing, topic tags, related videos, and the broader channel context behind the video.

Why are RPM and revenue numbers estimates?

Actual earnings depend on monetized playbacks, audience geography, seasonality, advertiser demand, and monetization status. CloutOrbit provides directional estimates for benchmarking, not exact payouts.

How should you use this page for content research?

Compare timing, topic tags, monetization signals, and adjacent videos from the same channel to spot formats, themes, and publishing patterns worth testing.